Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib versus adalimumab add-on to methotrexate in ACPA-positive rheumatoid arthritis
NL-OMON53878Phase 4Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of filgotinib in rheumatoid arthritis (RA) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Change in frequency of ACPA-expressing B cells secreting ACPA-IgG. Started Mar 2023; status: active, not recruiting.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON53878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53878.